Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany

Kerstin Herzer; Guido Gerken; Daniela Kroy; Frank Tacke; Julius Plewe; Dennis Eurich; Ulrich Spengler; Christian P. Strassburg; Martin Walter Welker; Sven Pischke; Martina Sterneck; Arianeb Mehrabi; Karl Heinz Weiss; Adam Herber; Thomas Berg; Tim Zimmermann; Peter R. Galle; Hauke Heinzow; Hartmut Schmidt; Antoaneta Markova; Yvonne Serfert; Michael P. Manns; Stefan Zeuzem; Heiner Wedemeyer

doi:10.1016/j.jhep.2018.07.001

Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany

Kerstin Herzer, Guido Gerken, Daniela Kroy, Frank Tacke, Julius Plewe, Dennis Eurich, Ulrich Spengler, Christian P. Strassburg, Martin Walter Welker, Sven Pischke, Martina Sterneck, Arianeb Mehrabi, Karl Heinz Weiss, Adam Herber, Thomas Berg, Tim Zimmermann, Peter R. Galle, Hauke Heinzow, Hartmut Schmidt, Antoaneta MarkovaYvonne Serfert, Michael P. Manns, Stefan Zeuzem, Heiner Wedemeyer

Research output: Contribution to journal › Letter › peer-review

13 Scopus citations

Original language	English
Pages (from-to)	982-984
Number of pages	3
Journal	Journal of Hepatology
Volume	69
Issue number	4
DOIs	https://doi.org/10.1016/j.jhep.2018.07.001
State	Published - Oct 2018
Externally published	Yes

Access to Document

10.1016/j.jhep.2018.07.001

Cite this

Herzer, K., Gerken, G., Kroy, D., Tacke, F., Plewe, J., Eurich, D., Spengler, U., Strassburg, C. P., Welker, M. W., Pischke, S., Sterneck, M., Mehrabi, A., Weiss, K. H., Herber, A., Berg, T., Zimmermann, T., Galle, P. R., Heinzow, H., Schmidt, H., ... Wedemeyer, H. (2018). Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany. Journal of Hepatology, 69(4), 982-984. https://doi.org/10.1016/j.jhep.2018.07.001

@article{f4dffd0f5e754d739be19304ba571461,

title = "Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany",

author = "Kerstin Herzer and Guido Gerken and Daniela Kroy and Frank Tacke and Julius Plewe and Dennis Eurich and Ulrich Spengler and Strassburg, {Christian P.} and Welker, {Martin Walter} and Sven Pischke and Martina Sterneck and Arianeb Mehrabi and Weiss, {Karl Heinz} and Adam Herber and Thomas Berg and Tim Zimmermann and Galle, {Peter R.} and Hauke Heinzow and Hartmut Schmidt and Antoaneta Markova and Yvonne Serfert and Manns, {Michael P.} and Stefan Zeuzem and Heiner Wedemeyer",

note = "Funding Information: K.H. reports personal fees from BMS, Janssen-Cilag as well as grants and personal fees from Novartis, Astellas, Chiesi and Biotest outside the submitted work. G.G. reports personal fees from AbbVie Deutschland GmbH & Co. KG, Bristol-Myers Squibb GmbH & Co. KGaA, Gilead Sciences GmbH, MSD Sharp & Dohme GmbH and Roche Pharma AG outside the submitted work. M-W.W. reports personal fees from AbbVie, Amgen, Bayer, BMS, Gilead, Novartis and Roche outside the submitted work. Sven Pischke reports personal fees from MSD, BMS and AbbVie outside the submitted work. K.H.W. reports non-financial support from Gilead and personal fees from AbbVie outside the submitted work. T.B. reports personal fees from Alexion, Bayer and Sirtex as well as grants and personal fees from AbbVie, BMS, Gilead, Intercept, Janssen, MSD/Merck, Merz, Novartis, Sequana Medical outside the submitted work. T.Z. reports grants from BMS as well as personal fees from AbbVie and Astellas. M.P.M reports grants and personal fees from AbbVie , Biotest, Boehringer Ingelheim , Bristol-Myers Squibb , Gilead , GlaxoSmithKline , Janssen , Merck (MSD), Novartis and Roche outside the submitted work. S.Z. reports personal fees from AbbVie, BMS, Gilead, Janssen and Merck/MSD outside the submitted work. H.W. reports grants, personal fees and non-financial support from Abbott, Roche Diagnostics; personal fees from Siemens, Janssen; grants and personal fees from BMS, Gilead, Novartis, Roche, Merck/MSD, AbbVie, Eiger, Falk and Falk Foundation; other from Transgene, non-financial support and other from MYR GmbH outside the submitted work. He received honoraria for consulting and research support by companies developing diagnostic tools and therapeutics for viral hepatitis. All other authors have nothing to disclose. Funding Information: K.H. reports personal fees from BMS, Janssen-Cilag as well as grants and personal fees from Novartis, Astellas, Chiesi and Biotest outside the submitted work. G.G. reports personal fees from AbbVie Deutschland GmbH & Co. KG, Bristol-Myers Squibb GmbH & Co. KGaA, Gilead Sciences GmbH, MSD Sharp & Dohme GmbH and Roche Pharma AG outside the submitted work. M-W.W. reports personal fees from AbbVie, Amgen, Bayer, BMS, Gilead, Novartis and Roche outside the submitted work. Sven Pischke reports personal fees from MSD, BMS and AbbVie outside the submitted work. K.H.W. reports non-financial support from Gilead and personal fees from AbbVie outside the submitted work. T.B. reports personal fees from Alexion, Bayer and Sirtex as well as grants and personal fees from AbbVie, BMS, Gilead, Intercept, Janssen, MSD/Merck, Merz, Novartis, Sequana Medical outside the submitted work. T.Z. reports grants from BMS as well as personal fees from AbbVie and Astellas. M.P.M reports grants and personal fees from AbbVie, Biotest, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Janssen, Merck (MSD), Novartis and Roche outside the submitted work. S.Z. reports personal fees from AbbVie, BMS, Gilead, Janssen and Merck/MSD outside the submitted work. H.W. reports grants, personal fees and non-financial support from Abbott, Roche Diagnostics; personal fees from Siemens, Janssen; grants and personal fees from BMS, Gilead, Novartis, Roche, Merck/MSD, AbbVie, Eiger, Falk and Falk Foundation; other from Transgene, non-financial support and other from MYR GmbH outside the submitted work. He received honoraria for consulting and research support by companies developing diagnostic tools and therapeutics for viral hepatitis. All other authors have nothing to disclose.",

year = "2018",

month = oct,

doi = "10.1016/j.jhep.2018.07.001",

language = "English",

volume = "69",

pages = "982--984",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier B.V.",

number = "4",

}

Herzer, K, Gerken, G, Kroy, D, Tacke, F, Plewe, J, Eurich, D, Spengler, U, Strassburg, CP, Welker, MW, Pischke, S, Sterneck, M, Mehrabi, A, Weiss, KH, Herber, A, Berg, T, Zimmermann, T, Galle, PR, Heinzow, H, Schmidt, H, Markova, A, Serfert, Y, Manns, MP, Zeuzem, S & Wedemeyer, H 2018, 'Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany', Journal of Hepatology, vol. 69, no. 4, pp. 982-984. https://doi.org/10.1016/j.jhep.2018.07.001

TY - JOUR

T1 - Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany

AU - Herzer, Kerstin

AU - Gerken, Guido

AU - Kroy, Daniela

AU - Tacke, Frank

AU - Plewe, Julius

AU - Eurich, Dennis

AU - Spengler, Ulrich

AU - Strassburg, Christian P.

AU - Welker, Martin Walter

AU - Pischke, Sven

AU - Sterneck, Martina

AU - Mehrabi, Arianeb

AU - Weiss, Karl Heinz

AU - Herber, Adam

AU - Berg, Thomas

AU - Zimmermann, Tim

AU - Galle, Peter R.

AU - Heinzow, Hauke

AU - Schmidt, Hartmut

AU - Markova, Antoaneta

AU - Serfert, Yvonne

AU - Manns, Michael P.

AU - Zeuzem, Stefan

AU - Wedemeyer, Heiner

N1 - Funding Information: K.H. reports personal fees from BMS, Janssen-Cilag as well as grants and personal fees from Novartis, Astellas, Chiesi and Biotest outside the submitted work. G.G. reports personal fees from AbbVie Deutschland GmbH & Co. KG, Bristol-Myers Squibb GmbH & Co. KGaA, Gilead Sciences GmbH, MSD Sharp & Dohme GmbH and Roche Pharma AG outside the submitted work. M-W.W. reports personal fees from AbbVie, Amgen, Bayer, BMS, Gilead, Novartis and Roche outside the submitted work. Sven Pischke reports personal fees from MSD, BMS and AbbVie outside the submitted work. K.H.W. reports non-financial support from Gilead and personal fees from AbbVie outside the submitted work. T.B. reports personal fees from Alexion, Bayer and Sirtex as well as grants and personal fees from AbbVie, BMS, Gilead, Intercept, Janssen, MSD/Merck, Merz, Novartis, Sequana Medical outside the submitted work. T.Z. reports grants from BMS as well as personal fees from AbbVie and Astellas. M.P.M reports grants and personal fees from AbbVie , Biotest, Boehringer Ingelheim , Bristol-Myers Squibb , Gilead , GlaxoSmithKline , Janssen , Merck (MSD), Novartis and Roche outside the submitted work. S.Z. reports personal fees from AbbVie, BMS, Gilead, Janssen and Merck/MSD outside the submitted work. H.W. reports grants, personal fees and non-financial support from Abbott, Roche Diagnostics; personal fees from Siemens, Janssen; grants and personal fees from BMS, Gilead, Novartis, Roche, Merck/MSD, AbbVie, Eiger, Falk and Falk Foundation; other from Transgene, non-financial support and other from MYR GmbH outside the submitted work. He received honoraria for consulting and research support by companies developing diagnostic tools and therapeutics for viral hepatitis. All other authors have nothing to disclose. Funding Information: K.H. reports personal fees from BMS, Janssen-Cilag as well as grants and personal fees from Novartis, Astellas, Chiesi and Biotest outside the submitted work. G.G. reports personal fees from AbbVie Deutschland GmbH & Co. KG, Bristol-Myers Squibb GmbH & Co. KGaA, Gilead Sciences GmbH, MSD Sharp & Dohme GmbH and Roche Pharma AG outside the submitted work. M-W.W. reports personal fees from AbbVie, Amgen, Bayer, BMS, Gilead, Novartis and Roche outside the submitted work. Sven Pischke reports personal fees from MSD, BMS and AbbVie outside the submitted work. K.H.W. reports non-financial support from Gilead and personal fees from AbbVie outside the submitted work. T.B. reports personal fees from Alexion, Bayer and Sirtex as well as grants and personal fees from AbbVie, BMS, Gilead, Intercept, Janssen, MSD/Merck, Merz, Novartis, Sequana Medical outside the submitted work. T.Z. reports grants from BMS as well as personal fees from AbbVie and Astellas. M.P.M reports grants and personal fees from AbbVie, Biotest, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Janssen, Merck (MSD), Novartis and Roche outside the submitted work. S.Z. reports personal fees from AbbVie, BMS, Gilead, Janssen and Merck/MSD outside the submitted work. H.W. reports grants, personal fees and non-financial support from Abbott, Roche Diagnostics; personal fees from Siemens, Janssen; grants and personal fees from BMS, Gilead, Novartis, Roche, Merck/MSD, AbbVie, Eiger, Falk and Falk Foundation; other from Transgene, non-financial support and other from MYR GmbH outside the submitted work. He received honoraria for consulting and research support by companies developing diagnostic tools and therapeutics for viral hepatitis. All other authors have nothing to disclose.

PY - 2018/10

Y1 - 2018/10

UR - http://www.scopus.com/inward/record.url?scp=85052862393&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2018.07.001

DO - 10.1016/j.jhep.2018.07.001

M3 - Letter

C2 - 30089577

AN - SCOPUS:85052862393

SN - 0168-8278

VL - 69

SP - 982

EP - 984

JO - Journal of Hepatology

JF - Journal of Hepatology

IS - 4

ER -